Patricia Schneider1, Diane Heels-Ansdell2, Lehana Thabane2, Michelle Ghert3,4. 1. Department of Surgery, McMaster University, Hamilton, ON, L8V 1C3, Canada. 2. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, L8S 4L8, ON, Canada. 3. Department of Surgery, McMaster University, Hamilton, ON, L8V 1C3, Canada. ghertm@mcmaster.ca. 4. Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, 711 Concession Street, B3 169A, Hamilton, L8V 1C3, ON, Canada. ghertm@mcmaster.ca.
Abstract
BACKGROUND:Limb salvage with endoprosthetic reconstruction is the current standard practice for the surgical management of lower extremity bone tumors in skeletally mature patients and typically includes tumor resection followed by the functional limb reconstruction with modular metallic and polyethylene endoprosthetic implants. However, owing to the complexity and length of these procedures, as well as the immunocompromised nature of patients treated with chemotherapy, the risk of surgical site infection (SSI) is high. The primary research objective of the Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial is to assess whether a 5-day regimen of post-operative antibiotics decreases the risk of SSI at 1 year post-operatively compared to a 1-day regimen. This article describes the statistical analysis plan for the PARITY trial. METHODS/ DESIGN: The PARITY trial is an ongoing multi-center, blinded parallel two-arm randomized controlled trial (RCT) of 600 participants who have been diagnosed with a primary bone tumor, a soft tissue sarcoma that has invaded the bone or oligometastatic bone disease of the femur or tibia that requires surgical resection and endoprosthetic reconstruction. This article describes the overall analysis principles, including how participants will be included in each analysis, the presentation of results, adjustments for covariates, the primary and secondary outcomes, and their respective analyses. Additionally, we will present the planned sensitivity and sub-group analyses. DISCUSSION: Our prior work has demonstrated (1) high rates of SSI after the treatment of lower extremity tumors by surgical excision and endoprosthetic reconstruction, (2) highly varied opinion and practice among orthopedic oncologists with respect to prophylactic antibiotic regimens, (3) an absence of applicable RCT evidence, (4) extensive support from international investigators to participate in a RCT, and (5) the feasibility of conducting a definitive RCT to evaluate a 5-day regimen of post-operative antibiotics in comparison with a 1-day regimen. TRIAL REGISTRATION: ClinicalTrials.gov NCT01479283 . Registered on 24 November 2011.
RCT Entities:
BACKGROUND: Limb salvage with endoprosthetic reconstruction is the current standard practice for the surgical management of lower extremity bone tumors in skeletally mature patients and typically includes tumor resection followed by the functional limb reconstruction with modular metallic and polyethylene endoprosthetic implants. However, owing to the complexity and length of these procedures, as well as the immunocompromised nature of patients treated with chemotherapy, the risk of surgical site infection (SSI) is high. The primary research objective of the Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial is to assess whether a 5-day regimen of post-operative antibiotics decreases the risk of SSI at 1 year post-operatively compared to a 1-day regimen. This article describes the statistical analysis plan for the PARITY trial. METHODS/ DESIGN: The PARITY trial is an ongoing multi-center, blinded parallel two-arm randomized controlled trial (RCT) of 600 participants who have been diagnosed with a primary bone tumor, a soft tissue sarcoma that has invaded the bone or oligometastatic bone disease of the femur or tibia that requires surgical resection and endoprosthetic reconstruction. This article describes the overall analysis principles, including how participants will be included in each analysis, the presentation of results, adjustments for covariates, the primary and secondary outcomes, and their respective analyses. Additionally, we will present the planned sensitivity and sub-group analyses. DISCUSSION: Our prior work has demonstrated (1) high rates of SSI after the treatment of lower extremity tumors by surgical excision and endoprosthetic reconstruction, (2) highly varied opinion and practice among orthopedic oncologists with respect to prophylactic antibiotic regimens, (3) an absence of applicable RCT evidence, (4) extensive support from international investigators to participate in a RCT, and (5) the feasibility of conducting a definitive RCT to evaluate a 5-day regimen of post-operative antibiotics in comparison with a 1-day regimen. TRIAL REGISTRATION: ClinicalTrials.gov NCT01479283 . Registered on 24 November 2011.
Entities:
Keywords:
Antibiotics; Bone sarcoma; Orthopedic oncology; Randomized controlled trial; Statistical analysis plan
Authors: Victor M Montori; P J Devereaux; Neill K J Adhikari; Karen E A Burns; Christoph H Eggert; Matthias Briel; Christina Lacchetti; Teresa W Leung; Elizabeth Darling; Dianne M Bryant; Heiner C Bucher; Holger J Schünemann; Maureen O Meade; Deborah J Cook; Patricia J Erwin; Amit Sood; Richa Sood; Benjamin Lo; Carly A Thompson; Qi Zhou; Edward Mills; Gordon H Guyatt Journal: JAMA Date: 2005-11-02 Impact factor: 56.272
Authors: Daphne Schreiber; Robert S Bell; Jay S Wunder; Brian O'Sullivan; Robert Turcotte; Bassam A Masri; Aileen M Davis Journal: Qual Life Res Date: 2006-05-27 Impact factor: 4.147
Authors: Carrol Gamble; Ashma Krishan; Deborah Stocken; Steff Lewis; Edmund Juszczak; Caroline Doré; Paula R Williamson; Douglas G Altman; Alan Montgomery; Pilar Lim; Jesse Berlin; Stephen Senn; Simon Day; Yolanda Barbachano; Elizabeth Loder Journal: JAMA Date: 2017-12-19 Impact factor: 56.272
Authors: Michelle Ghert; Patricia Schneider; Gordon Guyatt; Lehana Thabane; Roberto Vélez; Timothy O'Shea; R Lor Randall; Robert Turcotte; David Wilson; Jay S Wunder; André Mathias Baptista; Edward Y Cheng; Yee-Cheen Doung; Peter C Ferguson; Victoria Giglio; James Hayden; Diane Heels-Ansdell; Shah Alam Khan; Venkatesan Sampath Kumar; Paula McKay; Benjamin Miller; Michiel van de Sande; Juan P Zumárraga; Mohit Bhandari Journal: JAMA Oncol Date: 2022-03-01 Impact factor: 33.006